Developing a nomogram based on multiparametric magnetic resonance imaging for forecasting high-grade prostate cancer to reduce unnecessary biopsies within the prostate-specific antigen gray zone

BackgroundSince 1980s the application of Prostate specific antigen (PSA) brought the revolution in prostate cancer diagnosis. However, it is important to underline that PSA is not the ideal screening tool due to its low specificity, which leads to the possible biopsy for the patient without High-grade prostate cancer (HGPCa). Therefore, the aim of this study was to establish a predictive nomogram for HGPCa in patients with PSA 4–10 ng/ml based on Prostate Imaging Reporting and Data System version 2 (PI-RADS v2), MRI-based prostate volume (PV), MRI-based PV-adjusted Prostate Specific Antigen Density (adjusted-PSAD) and other traditional classical parameters.MethodsBetween January 2014 and September 2015, Of 151 men who were eligible for analysis were formed the training cohort. A prediction model for HGPCa was built by using backward logistic regression and was presented on a nomogram. The prediction model was evaluated by a validation cohort between October 2015 and October 2016 (n = 74). The relationship between the nomogram-based risk-score as well as other parameters with Gleason score (GS) was evaluated. All patients underwent 12-core systematic biopsy and at least one core targeted biopsy with transrectal ultrasonographic guidance.ResultsThe multivariate analysis revealed that patient age, PI-RADS v2 score and adjusted-PSAD were independent predictors for HGPCa. Logistic regression (LR) model had a larger AUC as compared with other parameters alone. The most discriminative cutoff value for LR model was 0.36, the sensitivity, specificity, positive predictive value and negative predictive value were 87.3, 78.4, 76.3, and 90.4%, respectively and the diagnostic performance measures retained similar values in the validation cohort (AUC 0.82 [95% CI, 0.76–0.89]). For all patients with HGPCa (n = 50), adjusted-PSAD and nomogram-based risk-score were positively correlated with the GS of HGPCa in PSA gray zone (r = 0.455, P = 0.002 and r = 0.509, P = 0.001, respectively).ConclusionThe nomogram based on multiparametric magnetic resonance imaging (mp-MRI) for forecasting HGPCa is effective, which could reduce unnecessary prostate biopsies in patients with PSA 4–10 ng/ml and nomogram-based risk-score could provide a more robust parameter of assessing the aggressiveness of HGPCa in PSA gray zone.

[1]  J. Parsons,et al.  4-Kallikrein Test and Kallikrein Markers in Prostate Cancer Screening. , 2016, The Urologic clinics of North America.

[2]  Armean Saema,et al.  PSA density and prostate cancer detection. , 2012, Journal of the Medical Association of Thailand = Chotmaihet thangphaet.

[3]  Shu Liao,et al.  Prostate volumes derived from MRI and volume-adjusted serum prostate-specific antigen: correlation with Gleason score of prostate cancer. , 2013, AJR. American journal of roentgenology.

[4]  Kai Yang,et al.  The use of prostate specific antigen (PSA) density in detecting prostate cancer in Chinese men with PSA levels of 4–10 ng/mL , 2008, Journal of Cancer Research and Clinical Oncology.

[5]  A. Jemal,et al.  Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.

[6]  Jeong Yeon Cho,et al.  PI-RADS version 2 for prediction of pathological downgrading after radical prostatectomy: a preliminary study in patients with biopsy-proven Gleason Score 7 (3+4) prostate cancer , 2016, European Radiology.

[7]  James A Hanley,et al.  20-year outcomes following conservative management of clinically localized prostate cancer. , 2005, JAMA.

[8]  Ivan Pedrosa,et al.  Diagnosis of relevant prostate cancer using supplementary cores from magnetic resonance imaging-prompted areas following multiple failed biopsies. , 2013, Magnetic resonance imaging.

[9]  N. Dubrawsky Cancer statistics , 1989, CA: a cancer journal for clinicians.

[10]  Andrew J Vickers,et al.  Systematic review of pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  Geert Trooskens,et al.  Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk Score. , 2016, European urology.

[12]  Shahrokh F. Shariat,et al.  Comparison of Nomograms With Other Methods for Predicting Outcomes in Prostate Cancer: A Critical Analysis of the Literature , 2008, Clinical Cancer Research.

[13]  H. Huisman,et al.  Interpatient variation in normal peripheral zone apparent diffusion coefficient: effect on the prediction of prostate cancer aggressiveness. , 2012, Radiology.

[14]  Shu Liao,et al.  Sparse Patch-Based Label Propagation for Accurate Prostate Localization in CT Images , 2013, IEEE Transactions on Medical Imaging.

[15]  P. Carroll,et al.  Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower , 2005 .

[16]  Jae Seok Lee,et al.  Transrectal Ultrasound versus Magnetic Resonance Imaging in the Estimation of Prostate Volume as Compared with Radical Prostatectomy Specimens , 2007, Urologia Internationalis.

[17]  B. G. Blijenberg,et al.  Prostate-cancer mortality at 11 years of follow-up. , 2012, The New England journal of medicine.

[18]  J. Epstein An update of the Gleason grading system. , 2010, The Journal of urology.

[19]  Ian M Thompson,et al.  Operating characteristics of prostate-specific antigen in men with an initial PSA level of 3.0 ng/ml or lower. , 2005, JAMA.

[20]  Andrew J. Vickers,et al.  The Relationship between Prostate-Specific Antigen and Prostate Cancer Risk: The Prostate Biopsy Collaborative Group , 2010, Clinical Cancer Research.

[21]  Werner Jaschke,et al.  Evaluation of the PI-RADS scoring system for mpMRI of the prostate: a whole-mount step-section analysis , 2015, World Journal of Urology.

[22]  Laurent Lemaitre,et al.  Current status of MRI for the diagnosis, staging and prognosis of prostate cancer: implications for focal therapy and active surveillance , 2009, Current opinion in urology.

[23]  Peter H Gann,et al.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends. , 2002, Journal of the National Cancer Institute.

[24]  Xavier Leroy,et al.  Prostate cancer diagnosis: multiparametric MR-targeted biopsy with cognitive and transrectal US-MR fusion guidance versus systematic biopsy--prospective multicenter study. , 2013, Radiology.

[25]  Angela Mariotto,et al.  Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. , 2009, Journal of the National Cancer Institute.

[26]  Katarzyna J Macura,et al.  Synopsis of the PI-RADS v2 Guidelines for Multiparametric Prostate Magnetic Resonance Imaging and Recommendations for Use. , 2016, European urology.

[27]  Koon Ho Rha,et al.  Prostate Cancer: PI-RADS Version 2 Helps Preoperatively Predict Clinically Significant Cancers. , 2016, Radiology.

[28]  T. Miyagawa,et al.  Combination of prostate imaging reporting and data system (PI‐RADS) score and prostate‐specific antigen (PSA) density predicts biopsy outcome in prostate biopsy naïve patients , 2017, BJU international.

[29]  Jurgen J Fütterer,et al.  Accuracy of multiparametric MRI for prostate cancer detection: a meta-analysis. , 2014, AJR. American journal of roentgenology.

[30]  Martijn G. Steffens,et al.  Comparative analysis of prostate cancer specific biomarkers PCA3 and ERG in whole urine, urinary sediments and exosomes , 2016, Clinical chemistry and laboratory medicine.

[31]  Chang Wook Jeong,et al.  Comparison of Prostate Volume Measured by Transrectal Ultrasonography and MRI with the Actual Prostate Volume Measured after Radical Prostatectomy , 2005, Urologia Internationalis.

[32]  B. Tombal,et al.  Free/total PSA ratio does not improve prediction of pathologic stage and biochemical recurrence after radical prostatectomy. , 2002, Urology.

[33]  Liqun Zhou,et al.  Prevalence and Risk Factors of Prostate Cancer in Chinese Men with PSA 4–10 ng/mL Who Underwent TRUS-Guided Prostate Biopsy: The Utilization of PAMD Score , 2015, BioMed research international.

[34]  P L Choyke,et al.  PI-RADS version 2: what you need to know. , 2015, Clinical radiology.

[35]  Roger Cutting,et al.  A Critical Analysis of the Literature in Women’s Leadership in Saudi Arabia , 2017 .